Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.
Drugs
Health
Pharma
Drugs
Health
Pharma
Wegovy’s weight-loss efficacy improves with higher dosage
HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.
Drugs
Health
Pharma
Governments, philanthropic partners pledge $170 million to WHO
HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.
Drugs
Health
Pharma
Novo Nordisk, Septerna in $2.2b deal to develop oral molecules
HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.
Drugs
Medical
Pharma
Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil
HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.
Drugs
Medical
Pharma
Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug
HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.
Drugs
Medical
Pharma
Novo Nordisk to pay US-based Gensaic $354 million upfront in licensing deal
HQ Team March 5, 2025: Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s.
Drugs
Health
Medical
Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Drugs
Health
Medical
Novo Nordisk, Valo expand pact to include obesity, diabetic drugs
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.
Uncategorized
Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.